title: Candidate HIV/AIDS vaccines: lessons learned from the World's first phase III efficacy trials.
authors.forename: Donald P
authors.initials: DP
authors.lastname: Francis
authors.forename: William L
authors.initials: WL
authors.lastname: Heyward
authors.forename: Vladimir
authors.initials: V
authors.lastname: Popovic
authors.forename: Patti
authors.initials: P
authors.lastname: Orozco-Cronin
authors.forename: Karin
authors.initials: K
authors.lastname: Orelind
authors.forename: Carolyn
authors.initials: C
authors.lastname: Gee
authors.forename: Adrian
authors.initials: A
authors.lastname: Hirsch
authors.forename: Tina
authors.initials: T
authors.lastname: Ippolito
authors.forename: Aimee
authors.initials: A
authors.lastname: Luck
authors.forename: Michael
authors.initials: M
authors.lastname: Longhi
authors.forename: Vineeta
authors.initials: V
authors.lastname: Gulati
authors.forename: Nathan
authors.initials: N
authors.lastname: Winslow
authors.forename: Marc
authors.initials: M
authors.lastname: Gurwith
authors.forename: Faruk
authors.initials: F
authors.lastname: Sinangil
authors.forename: Phillip W
authors.initials: PW
authors.lastname: Berman
mesh_terms: D016915:AIDS Vaccines; D017326:Clinical Trials, Phase III as Topic; D006076:Government; D015658:HIV Infections / Q000517:prevention & control*; D006801:Humans; D018579:Patient Selection; D012107:Research Design
chemical_list: D016915:AIDS Vaccines; C112734:AIDSVAX